Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction
- 1 January 2008
- journal article
- review article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 75 (1), 2-16
- https://doi.org/10.1016/j.bcp.2007.08.007
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Dual dopamine–5-HT releasers: potential treatment agents for cocaine addictionTrends in Pharmacological Sciences, 2006
- Structure−Activity Relationship Studies on a Novel Series of (S)-2β-Substituted 3α-[Bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane Analogues for in Vivo InvestigationJournal of Medicinal Chemistry, 2006
- The neuroscience of addictionNature Neuroscience, 2005
- Effects of 4′-Chloro-3α-(diphenylmethoxy)-tropane on Mesostriatal, Mesocortical, and Mesolimbic Dopamine Transmission: Comparison with Effects of CocaineThe Journal of pharmacology and experimental therapeutics, 2005
- Response requirements and unit dose modify the effects of GBR 12909 on cocaine-maintained behavior.Experimental and Clinical Psychopharmacology, 2000
- Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration proceduresNeuropsychopharmacology, 1996
- The dopamine hypothesis of the reinforcing properties of cocaineTrends in Neurosciences, 1991
- High affinity dopamine reuptake inhibitors as potential cocaine antagonists: A strategy for drug developmentLife Sciences, 1990
- Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [3H]GBR12935 binding and [3H]dopamine uptakeNeurochemistry International, 1989
- Tight binding dopamine reuptake inhibitors as cocaine antagonistsFEBS Letters, 1989